Business
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita’s potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026 Rejuva gene therapy platform advancing toward first-in-human studies; first CTA m
About this update from Fractyl Health, Inc.
[{"type":"image","alt":"Fractyl Health, Inc.","displaySize":"","headline":null,"caption":"Fractyl Health, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/grE4KlKD7t64vNihlXguCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5","width":300,"height":104}},"lazy":false},{"type":"text","content":"REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita’s potential to maintain weight loss after GLP-1 discontinuation in the real world","length":191,"tagName":"p"},{"type":"text","content":"REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance","length":105,"tagName":"p"},{"type":"text","content":"REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026","length":120,"tagName":"p"},{"type":"text","content":"Rejuva gene therapy platform advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected in June 2025","length":132,"tagName":"p"},{"type":"text","content":"Conference call today at 4:30 p.m. ET","length":37,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced first quarter 2025 financial results and provided business updates highlighting rapid clinical and operational momentum.","length":374,"tagName":"p"},{"type":"text","content":"“At Fractyl, we are answering one of the most urgent questions in obesity care: how to maintain weight loss after patients discontinue GLP-1 therapy,” said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health. “We are accelerating on our bold ambition to create lasting, disease-modifying therapies. With the REMAIN-1 Pivotal Cohort fully enrolled ahead of schedule, early REVEAL-1 Cohort data demonstrating promising weight stability, and Rejuva advancing toward the clinic, we are executing with urgency a...